Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has earned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 1-year consensus target price of $29.63 for the company and are forecasting that the company will post ($0.48) earnings per share for the current quarter, according to Zacks. Zacks has also given Milestone Pharmaceuticals an industry rank of 58 out of 256 based on the ratings given to its competitors.
MIST has been the subject of several analyst reports. Oppenheimer initiated coverage on shares of Tilray in a report on Tuesday, June 4th. They issued a “market perform” rating for the company. Cowen reissued a “buy” rating on shares of Odonate Therapeutics in a report on Monday, June 3rd. Jefferies Financial Group reissued a “buy” rating and issued a GBX 3,000 ($39.20) target price on shares of in a report on Monday, June 3rd. CIBC initiated coverage on shares of Uber Technologies in a report on Tuesday, June 4th. They issued an “outperform” rating and a $55.00 target price for the company. Finally, Piper Jaffray Companies lowered shares of Cypress Semiconductor from an “overweight” rating to a “neutral” rating in a report on Monday, June 3rd.
Shares of NASDAQ:MIST traded up $0.46 during trading on Friday, hitting $19.60. The company’s stock had a trading volume of 696 shares, compared to its average volume of 19,712. The company has a 50-day simple moving average of $21.64. Milestone Pharmaceuticals has a 12 month low of $15.09 and a 12 month high of $27.95.
Milestone Pharmaceuticals Company Profile
Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.
Featured Story: Economic Bubble
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.